Jakavi offers new treatment option in myelofibrosis

Jakavi (ruxolitinib) is a selective inhibitor of JAK 1 and 2 for use in disease-related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia.

The starting dose of Jakavi is dependent on baseline platelet count
The starting dose of Jakavi is dependent on baseline platelet count

PHARMACOLOGY

Ruxolitinib inhibits the Janus-associated kinases (JAK) 1 and 2, which mediate the signalling of molecules involved in haematopoiesis and immune function.1 In myelofibrosis, there is typically a dysfunction of the JAK pathway.

CLINICAL STUDIES

Ruxolitinib displayed efficacy in two double-blind studies in patients with intermediate-2 or high-risk myelofibrosis. The first (COMFORT-I) compared ruxolitinib with placebo and the second (COMFORT-II) used best available therapy (BAT) as the comparator treatment.2,3

Reduced spleen volume

In COMFORT-I (n=309), 41.9% of ruxolitinib patients achieved a ≥35% reduction in spleen volume at 24 weeks compared with 0.7% of placebo patients (p<0.001). This reduction was maintained for 48 weeks or more in 67% of those who responded. Ruxolitinib was also associated with a significant survival advantage compared with placebo (13 versus 24 deaths, hazard ratio 0.5; p=0.05).2

In COMFORT-II (n=219), 28% of patients who received ruxolitinib had a ≥35% reduction in spleen volume at 48 weeks compared with 0% of patients who received BAT (p<0.001).3 In addition, there was a 56% reduction in mean palpable spleen length at 48 weeks in the ruxolitinib group compared with a 4% increase in the BAT group. The most common therapies in the BAT group were hydroxycarbamide and glucocorticoids.3

Well tolerated

Ruxolitinib was associated with symptom improvement and was generally well tolerated, with anaemia and thrombocytopenia the most commonly reported adverse effects.2,3

References:

1.    Jakavi Summary of Product Characteristics, August 2012
2.    Verstovsek S et al. N Engl J Med 2012; 366: 799-807.
3.    Harrison C et al. N Engl J Med 2012; 366: 787-98.

View Jakavi drug record

Further information: Novartis

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.